Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2022-05-05 00:00:00 ET · period of report 2022-05-05 · accession 0001567619-22-009639 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-05 | 2022-05-05 | ARQT | Watanabe Todd Franklin | Pres, CEO, Dir | S - Sale | $21.76 | -1,000 | 658.7K | -0.2% | -$21.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-05 | S | D | 1,000 | $21.76 | 658,667 | D | — | — | (F2) Includes 109,925 restricted stock units. |